<DOC>
	<DOCNO>NCT00148785</DOCNO>
	<brief_summary>When individual infect HIV start treatment HIV medication , effect drug last limited period time , often development drug resistance HIV virus . When happens , patient switch different combination HIV medication . However , since availability new HIV drug active resistant virus limit , HIV care provider resort curtail medication contain three protease inhibitor ( PIs ) . The reason Norvir ( ritonavir ) , PI ability boost increase blood level PIs way sometimes overcome resistance HIV virus . In addition , may difficult virus overcome two drug high blood level , overcome one . For reason , many clinician use Norvir combination two PIs , include Crixivan ( indinavir ) plus Lexiva ( fosamprenavir ) , treat patient expose many HIV medication . While may case , researcher also know two PIs combine , effect drug may blood level drug could different . For example , researcher know recent study combination Norvir , Lexiva , Kaletra , another PI , lead unacceptably low level Kaletra Lexiva . Because researcher always assume multiple HIV medication combine , level remain high enough effective , investigator think always reasonable , combination drug use HIV-infected patient , effect combination level drug combination investigate . AIMS : The aim pilot study therefore examine blood level Crixivan , Lexiva , Norvir three drug use together part combination treatment HIV infection . METHODS : Fifteen ( 15 ) HIV-infected volunteer already treat Crixivan Norvir contain regimen recruit Grady Infectious Disease Clinic ( IDP ) . Lexiva add regimen 5 day , end participant admit Grady General Clinical Research Center ( GCRC ) blood sample collect 9 different time point 12 hour measurement blood drug level . Pharmacokinetic Analysis : The blood concentration Crixivan , Lexiva , Norvir measure special technique know reverse-phase high-performance liquid chromatography ultraviolet detection . Statistical Analysis : The blood level information summarize statistical method . The researcher compare level Lexiva combination historically publish level Lexiva study Lexiva plus Norvir ; Crixivan study Crixivan plus Norvir . A difference 30 % drug level study historical report consider significant difference .</brief_summary>
	<brief_title>A Pharmacokinetic ( PK ) Study Combination Indinavir , Ritonavir , Amprenavir</brief_title>
	<detailed_description>BACKGROUND : Because potent antiviral effect , protease inhibitor ( PI ) -containing antiretroviral regimen ( ARV ) become one cornerstone HIV treatment . Success use however dampen increase emergence resistant viral gene mutation consequent treatment failure . Since availability newer antiviral agent activity resistant viral strain limit , clinician increasingly resort ritonavir ( RTV ) enhance dual PI therapy treat salvage patient . In presence RTV , metabolism concomitantly administer PIs cytochrome P450 3A4 ( CYP3A4 ) isoenzyme inhibit ; high plasma tissue drug level maintain less variability . The enhanced pharmacokinetics result prolonged suppression viral replication include strain moderate phenotypic resistance lead improve therapeutic outcome . RTV enhance dual PI therapy offer additional advantage combination PIs different non-overlapping mutation pattern would expect delay emergence viral resistance , couple notion selection resistance two agent may require great number mutation require overcome single PI . Furthermore , combination regimen often result reduction pill burden , food restriction , may associate tolerable side effect profile . For reason , RTV enhance indinavir ( IDV ) fos-amprenavir ( fos-APV ) combination appear promising salvage therapy two agent pharmacokinetically enhance RTV , unique resistant mutation profile compare PIs . Additionally , since clinically limit interaction know occur fos-APV lopinavir/ritonavir ( LPV/r ) , interaction IDV , fos-APV , RTV may different manner could clinically beneficial salvage therapy . Importantly , evaluate IDV/fos-APV/RTV dose 800/700/100 mg bid anticipate fos-APV may lower IDV concentration similarly lopinavir ( LPV ) , although likely less extent ; dual benefit enhance efficacy improve tolerability could achieve . The pharmacokinetic profile combination regimen therefore merit evaluation allay concern clinically important drug-drug interaction introduction clinical practice . AIMS : The aim pilot study therefore evaluate impact addition fos-APV pharmacokinetic parameter ( plasma trough concentration ( Cmin ) , peak concentration ( Cmax ) , elimination half-life ( t1/2β ) , area concentration-time curve ( AUC12 ) ) IDV RTV steady state HIV infect patient . METHODS : Fifteen HIV-infected subject already treat IDV/RTV contain ARV therapy ( 800/100 mg bid ) recruit Grady Infectious Disease Clinic ( IDP ) . Initially , blood sample collect time 0 , 1 , 2 , 3 , 4 , 6 , 8 , 10 , 12 hour baseline 12-hour pharmacokinetics study RTV IDV . Fos-APV 700 mg bid add regimen 5 day . At end blood sample collect time 0 , 1 , 2 , 3 , 4 , 6 , 8 , 10 , 12 hour IDV , RTV APV pharmacokinetic parameter . Pharmacokinetic Analysis : Plasma concentration IDV , APV , RTV determine sensitive validated reverse-phase high-performance liquid chromatography ( HPLC ) . The Cmax , Cmin , t1/2β , AUC12 PIs determine use non-compartmental pharmacokinetic method . Statistical Analysis : IDV RTV pharmacokinetic index addition fos-APV compare use non-parametric two-sided pair t-test .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>Age 18 year Diagnosis HIV infection AIDS previously establish HIV ELISA test confirm Western blot analysis Must take tolerate IDV/RTV 800/100 mg bid part antiretroviral regimen . Hepatic abnormality : alanineaminotransferase ( ALT ) , aspartate aminotransferase ( AST ) total bilirubin ( TBR ) great 3x upper limit normal Renal insufficiency : serum creatinine great 2 mg/dl Coinfection hepatitis B and/or C viruses Pregnant breastfeeding Use concurrent medication know affect IDV APV concentration significantly ( e.g . rifampin , rifabutin , nonnucleoside reverse transcriptase inhibitor [ NNRTI ] , PIs , St John 's Wort , herbal preparation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Antiretroviral drug</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Fosamprenavir</keyword>
</DOC>